Lack of association between the rs2294008 polymorphism in the prostate stem cell antigen gene and colorectal neoplasia: a case-control and immunohistochemical study

BMC Research Notes

Emad M El-Omar³  Graeme I Murray²  Nicky Fyfe²  Georgina L Hold¹  Umesh Basavaraju¹  Paul Lochhead¹  Christopher Smith¹ 

[1] Gastrointestinal Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, Scotland;Department of Pathology, University of Aberdeen, Aberdeen, AB25 2ZD, Scotland;Room 6.20, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, Scotland

关键词: Immunohistochemistry;    Case control study;    Prostate stem cell antigen;    Single nucleotide polymorphism;    Polyp;    Adenoma;    Rectal cancer;    Colon cancer;    Colorectal cancer;    Colorectal neoplasia;   

Others  :  1166100
DOI  :  10.1186/1756-0500-5-371

 received in 2012-04-26, accepted in 2012-07-06,  发布年份 2012

【 摘 要 】

Background

Prostate stem cell antigen (PSCA) has been implicated in the pathogenesis of several solid tumours, either due to changes in protein expression, or through association with the rs2294008 polymorphism in the PSCA gene. To our knowledge, the role of PSCA in the development of colorectal neoplasia has not been explored. We performed a genotyping study to assess for associations between the rs2294008 polymorphism and risk of adenomatous polyps and colorectal cancer. DNA samples were available from 388 individuals with colorectal neoplasia and 496 controls, all of whom had undergone screening colonoscopy. In addition, we performed immunohistochemical staining for PSCA in colonic tissue representing all stages of the adenoma-carcinoma sequence.

Results

No genotypic associations were found between the rs2294008 polymorphism and the risk of colorectal adenomata or cancer. Immunohistochemical staining did not reveal any alteration in PSCA expression accompanying the adenoma-carcinoma sequence.

Conclusion

From these data it seems unlikely that PSCA has a role in the initiation or progression of colorectal neoplasia.

【 授权许可】

   
2012 Smith et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998, 95(4):1735-1740.
• [2]Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19(10):1288-1296.
• [3]Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE: Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171(3):1117-1121.
• [4]Liu WK, Jiang XY, Zhang ZX: Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie 2010, 33(5):241-245.
• [5]Elsamman EM, Fukumori T, Tanimoto S, Nakanishi R, Takahashi M, Toida K, Kanayama HO: The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 2006, 98(3):668-673.
• [6]Cao D, Ji H, Ronnett BM: Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 2005, 24(1):67-72.
• [7]Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001, 61(12):4660-4665.
• [8]Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH: Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001, 61(11):4320-4324.
• [9]Kawaguchi T, Sho M, Tojo T, Yamato I, Nomi T, Hotta K, Hamada K, Suzaki Y, Sugiura S, Kushibe K, Nakajima Y, Taniguchi S: Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol 2010, 40(4):319-326.
• [10]Geiger KD, Hendruschk S, Rieber EP, Morgenroth A, Weigle B, Juratli T, Senner V, Schackert G, Temme A: The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol Rep 2011, 26(1):13-21.
• [11]Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, Park SR, Kim CG, Choi IJ, Yoshida T, Nakamura Y, Hirohashi S, Study Group of Millennium Genome Project for Cancer: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008, 40(6):730-740.
• [12]Bahrenberg G, Brauers A, Joost HG, Jakse G: Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000, 275(3):783-788.
• [13]Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, Choi IJ, Saito A, Yanagihara K, Kanai Y, Ohnami S, Chiwaki F, Sasaki H, Sakamoto H, Yoshida T, Saeki N: Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer 2012, 51(1):30-41.
• [14]Saeki N, Gu J, Yoshida T, Wu X: Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010, 16(14):3533-3538.
• [15]Lochhead P, Frank B, Hold GL, Rabkin CS, Ng MT, Vaughan TL, Risch HA, Gammon MD, Lissowska J, Weck MN, Raum E, Muller H, Illig T, Klopp N, Dawson A, McColl KE, Brenner H, Chow WH, El-Omar EM: Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. Gastroenterology 2011, 140(2):435-441.
• [16]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [17]Jeffery N, McLean MH, El-Omar EM, Murray GI: The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 2009, 54(7):820-828.
• [18]McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NA, El-Omar EM: COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology 2008, 52(7):806-815.
• [19]Zhao Z, Liu J, Li S, Shen W: Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2009, 69(12):1292-1302.
• [20]Zhao Z, Zeng G, Ma W, Ou L, Liang Y: Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen-independent progression in advanced prostate cancer. Int J Cancer 2011, 131(4):902-910.
• [21]Joung JY, Cho KS, Kim JE, Seo HK, Chung J, Park WS, Choi MK, Lee KH: Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol 2010, 101(2):145-148.
• [22]Wang M, Bai J, Tan Y, Wang S, Tian Y, Gong W, Zhou Y, Gao Y, Zhou J, Zhang Z: Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int J Cancer 2011, 129(5):1207-1213.
• [23]Marra E, Uva P, Viti V, Simonelli V, Dogliotti E, De Rinaldis E, Lahm A, La Monica N, Nicosia A, Ciliberto G, Palombo F: Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer 2010, 10:129. BioMed Central Full Text
• [24]Gumley TP, McKenzie IF, Sandrin MS: Tissue expression, structure and function of the murine Ly-6 family of molecules. Immunol Cell Biol 1995, 73(4):277-296.
• [25]Chimienti F, Hogg RC, Plantard L, Lehmann C, Brakch N, Fischer J, Huber M, Bertrand D, Hohl D: Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 2003, 12(22):3017-3024.
• [26]Moriwaki Y, Yoshikawa K, Fukuda H, Fujii YX, Misawa H, Kawashima K: Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands. Life Sci 2007, 80(24–25):2365-2368.
• [27]Hruska M, Keefe J, Wert D, Tekinay AB, Hulce JJ, Ibanez-Tallon I, Nishi R: Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci 2009, 29(47):14847-14854.
• [28]Livak KJ: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999, 14(5–6):143-149.
• [29]Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, Pieri F, Fraternali-Orcioni G, Pileri SA: The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998, 51(7):506-511.